Download - Cipla vs Ranbaxy Research Report
-
8/20/2019 Cipla vs Ranbaxy Research Report
1/39
-
8/20/2019 Cipla vs Ranbaxy Research Report
2/39
.Assstant Pro"essorBhumika Bhayashaly
Research Metho(o!o)-/Sakshi !yai "ushyant Malik Pra#hi Ane$a
-
8/20/2019 Cipla vs Ranbaxy Research Report
3/39
AC%N&'L("G(M(N!
I a% than0"#! to the a!%)ht- 1o( 'ho has )2en %e
the opport#nt- to e3press o#r sncere than0s an( (eep
post )ratt#(e to a!! those peop!e 'ho e3ten(e( ther
'ho!e hearte( co4operaton an( he!pe( %e co%p!etn)
the pro5ect report s#ccess"#!!-6
I 'o#!( !0e to than0 o#r %entor Miss. Shruti Mittal
'ho )#(e( %e a !ot co%p!etn) ths pro5ect report6
I a% a!so than0"#! to o#r (rector Mr. Sa#hin Goel7 'ho
)a2e %e s#ch opport#nt- to prepare a pro5ect report
that '!! enhance o#r practca! 0no'!e()e & corporate
a'areness6
Last +#t not the !east ! 'o#!( !0e to than0s to the
"raternt- o" SRCM "or %entorn)7 )#(n)7 s#pportn)7
teachn) & coachn) %e n "#!! capact- that has s#re!-
enrche( %- persona!t- as a 'ho!e6
Priyanshu Goel
Bhumika BhayashalySakshi !yai
"ushyant Malik Pra#hi Ane$a
-
8/20/2019 Cipla vs Ranbaxy Research Report
4/39
DECLARATION
8e here+- (ec!are that ths pro5ect report s o#r o'n
research 'or0 an( to the +est o" %- 0no'!e()e &
+e!e"6 Matera! contans ths report nether pre2o#s!-
p#+!she( or 'rtten +- an- other person nor accepte(
"or the a'ar( o" an- other %aster (e)ree +- #n2erst-
o" h)her !earnn)6
-
8/20/2019 Cipla vs Ranbaxy Research Report
5/39
PR()AC(
So%eone has r)ht!- sa( that practca!
0no'!e()e s "ar +etter than c!assroo% teachn)6
D#rn) ths pro5ect 'e "#!!- rea!9e( ths an( ca%e to
0no' a+o#t ho' a cons#%er chooses a%on) a 2are(
ran)e o" pro(#cts a2a!a+!e to h%6
Ths s the speca!9aton research pro5ect
on a co%part2e %ar0et st#(- o" Cp!a & Ran+a3-
Phar%ace#tca! +ran(s6 The o+5ect2e o" ths st#(- s to
)an 0no'!e()e a+o#t the %ar0et share an(
co%petton +et'een the t'o +ran(s6
D#rn) the pro5ect 'e researche( on ho'
the %ar0et share s capt#re( an( postonn) o" the
pro(#ct create( +- Cp!a an( Ran+a3- n the %n( o"
c#sto%ers6 A s#r2e- 'as a!so (one "or #n(erstan(n)
cons#%er +#-n) pattern an( pre"erences6
Th#s7 ths st#(- s +ase( on
co%part2e ana!-ss o" the %ar0et share +et''en the
+ran(s6
-
8/20/2019 Cipla vs Ranbaxy Research Report
6/39
CONTENTS
Preface
Acknowledgement
Declaration
PART A
*. E3ec#t2e S#%%ar- :4;
+. In(#str- Pro$!e
,. Co%pan- Pro$!e ;?4
-
8/20/2019 Cipla vs Ranbaxy Research Report
7/39
OVERVIE8 OF PHARMACEUTICAL
SECTOR
Acco#ntn) "or t'o percent o" the 'or!(s phar%ace#tca!%ar0et7 the In(an phar%ace#tca! sector has an est%ate(%ar0et 2a!#e o" a+o#t US +!!on6 Its at ;th ran0 n ter%s o"tota! phar%ace#tca! pro(#cton an( @=th n ter%s o" 2a!#e6 It s)ro'n) at an a2era)e rate o" B6: G an( s e3pecte( to )ro' toUS @: +!!on +- :?@?6
O2er the !ast t'o -ears the phar%ace#tca! %ar0et 2a!#e hasncrease( to a+o#t US =
-
8/20/2019 Cipla vs Ranbaxy Research Report
8/39
the chan)es that too0 p!ace n the patent !a'7 chan)e o"
process patent to pro(#ct patent7 ha2e he!pe( n re(#cn) the
rs0 o" !oss "or nte!!ect#a! propert-6
-
8/20/2019 Cipla vs Ranbaxy Research Report
9/39
CIPLA
Cp!a s one o" the !ar)est phar%a co%panes n the(o%estc %ar0et an( has presence n "or%#!atons an( +#!0
(r#)s %an#"act#rn)6 A!! the +#!0 (r#) %an#"act#rn)
"ac!tes o" the co%pan- ha2e +een appro2e( +- 2aro#s
a#thortes nc!#(n) the US FDA6 On the e3ports "ront7 the
co%pan- has strate)c a!!ances 'th )enerc %an#"act#res
s#ch as 8atson7 M-!an7 an( Te2e "or s#pp!- o" +#!0 (r#)s6
In#or4orate5 @>=<
Reistere5&6#e
Cp!a L%te(7 Cp!a Ho#se7 Penns#!a *#snessPar07 1anpatrao Ka(a% Mar)7 Lo'er Pare!7M#%+a ;?? ?@=
Chairman Dr6 Y#s#" K6 Ha%e(
Non7
(8e#uti9e:i#e7Chairman
Mr6 M6K6 Ha%e(
Listin E#t- Shares, *SE L%te( an( Natona! Stoc0E3chan)e o" In(a L%te(1!o+a! Depostor- Recepts, L#3e%+o#r) Stoc0E3chan)e
!urno9er USD @6B +!!on
(m4loyees :?7???J
A44ro9als US FDA7 8HO41ene2a7 MHRA4UK7 T1A4A#stra!a7SUKL4S!o2a0 Rep#+!c7 APVMA4A#stra!a7 MCC4So#th A"rca7 PIC41er%an-7 Dansh Me(ca!A)enc-7 ANVISA4*ra9!7 INVIMA4 Co!o%+a7 NDA4U)an(a7 Depart%ent o" Hea!th4Cana(a an( MOH4
Sa#( Ara+a7 a%on) others
-
8/20/2019 Cipla vs Ranbaxy Research Report
10/39
;ihlihts Contn#o#s nno2aton n R &D 'th
=?J 'or!( $rsts6
O2er @7
-
8/20/2019 Cipla vs Ranbaxy Research Report
11/39
It s an nte)rate(7 research +ase(7 nternatona!
phar%ace#tca! co%pan-7 pro(#cn) a '(e ran)e o"
#a!t-7 aor(a+!e )enerc %e(cnes7 tr#ste( +-hea!thcare pro"essona!s an( patents across )eo)raphes6
The Co%pan- has a )!o+a! "ootprnt n ;= co#ntres7 'or!(4
c!ass %an#"act#rn) "ac!tes n co#ntres an( ser2es
c#sto%ers n o2er @:< co#ntres6
In #ne :??7 Ran+a3- entere( nto an a!!ance 'th one o"
the !ar)est apanese nno2ator co%panes7 Dach San0-o
Co%pan- Lt(67 to create an nno2ator an( )enercphar%ace#tca! po'erho#se6
The co%+ne( entt- no' ran0s a%on) the top :?
phar%ace#tca! co%panes7 )!o+a!!-6
-
8/20/2019 Cipla vs Ranbaxy Research Report
12/39
OBJECTIVES OF RESEARCH
The p#rpose o" research s to (sco2er ans'ers to #estons
thro#)h the app!caton o" scent$c proce(#res6 The %an a%
o" research s to $n( o#t the tr#th 'hch s h((en an( 'hch
has not +een (sco2ere( as -et6 Tho#)h each research st#(-
has ts o'n spec$c p#rpose +#t the research o+5ect2es can +e
!ste( nto a n#%+er o" +roa( cate)ores7 as "o!!o'n)
@6 To )an "a%!art- 'th a pheno%enon or to ache2e ne'
ns)hts nto t6 St#(es 'th ths o+5ect n 2e' are ter%e(
as e3p!orator- or "or%#!at2e research st#(es6
:6 To portra- acc#rate!- the characterstcs o" a partc#!ar
n(2(#a!7 st#aton or a )ro#p6 St#(es 'th ths o+5ect n
2e' are 0no'n as (escrpt2e research st#(es6=6 To (eter%ne the "re#enc- 'th 'hch so%ethn) occ#rs
or 'th 'hch t s assocate( 'th so%ethn) e!se6 St#(es
'th ths o+5ect n 2e' are 0no'n as (a)nostc research
st#(es6
;6 To test a h-pothess o" a cas#a! re!atonshp +et'een
2ara+!es6 S#ch st#(es are 0no'n as h-pothess4testn)research st#(es6
-
8/20/2019 Cipla vs Ranbaxy Research Report
13/39
SIGNIFICANCE OF RESEARCH
A!! process s +orn o" n#r-6 Do#+t s o"ten +etter than
o2ercon$(ence7 "or t !ea(s to n#r- an( n#r- !ea(s to
n2enton6 Is a "a%o#s H#(son Ma3% n conte3t o" 'hch the
s)n$cance o" research can 'e!! +e #n(erstoo( Increase(
a%o#nts o" research %a0e pro)ress poss+!e6
Research nc#!cates scent$c an( n(#ct2e thn0n) an( t
pro%otes the (e2e!op%ent o" !o)ca! ha+ts o" thn0n) an(
or)an9aton6
The ro!e o" research n se2era! $e!(s o" app!e( econo%cs7
'hether re!ate( to +#sness or to the econo%- as a 'ho!e7 has
)reat!- ncrease( n %o(ern t%es6 The ncreasn) co%p!e3
nat#re o" +#sness an( )o2ern%ent has "oc#se( attenton on
the #se o" research n so!2n) operatona! pro+!e%s6 Research7
as an a( to econo%c po!c-7 has )ane( a((e( %portance7
+oth "or )o2ern%ent an( +#sness6
-
8/20/2019 Cipla vs Ranbaxy Research Report
14/39
Researc Me!"#"$"%&
Research %etho(o!o)- s a 'a- to s-ste%atca!!- so!2e the
research pro+!e%6 It %a- +e #n(erstoo( as a scence o"
st#(-n) ho' research s (one scent$ca!!-6 In t 'e st#(- the
2aro#s steps that are )enera!!- a(opte( +- a researcher n
st#(-n) hs research pro+!e% a!on) 'th the !o)c +ehn(
the%6 It s necessar- "or the researcher to 0no' not on!- the
research %etho(s or techn#es +#t a!so the %etho(o!o)-6
Resear#h "esin<
!aret Po4ulation< Pop#!aton o" the research s thecons#%ers 'ho are 'e!! a'are o" the %e(cnes an( 'ho area+o2e @ -ears o" a)e6
Resear#h "esin < Descrpt2e Research
Sam4lin unit< Sa%e as the sa%p!e e!e%ent6
Sam4lin !e#hni=ue< Con2enence sa%p!n)6
Sam4le Si>e <
-
8/20/2019 Cipla vs Ranbaxy Research Report
15/39
o#rna!s8e+stesReports
Data Ana!-ss
#es, Are You A?are &@ Ci4la Rana8y
Com4any 4ro5u#ts
Ans6 , .A/ YES .*/ N?
CIPLA
REN*AY
?
<
@?
@<
:?
:<
=?
=<
;?
;<
-
8/20/2019 Cipla vs Ranbaxy Research Report
16/39
-
8/20/2019 Cipla vs Ranbaxy Research Report
17/39
#es, "o You ;a9e Ci4la Rana8y Com4anyDs
Pro5u#t
Ans , .A/ YES .*/ NO
CIPLA PRODUCT RAN*AY PRODUCT
?
<
@?
@<
:?
:<
=?
=<
;?
;<
Cp!a G
Ran+a3- @;G
Peop!e #se Cp!a co%pan- pro(#ct %ore than Ran+a3-
pro(#ct6
-
8/20/2019 Cipla vs Ranbaxy Research Report
18/39
#es, In 8hch Co%pan- Yo# Dea! 8th Most
Ans, .A/ Cp!a .*/ Ran+a3-
CIPLA RAN*AY
?
<
@?
@<
:?
:<
=?
=<
cp!a G
Ran+a3- =;G
Cp!a sa!es s %ore than Ran+a3-6
-
8/20/2019 Cipla vs Ranbaxy Research Report
19/39
#es, 'hat Makes You !o Choose !his Com4any
Ans6 .A/ H)h De%an( .*/ H)h Pro$t
.C/ P#+!ct- O" Pro(#ct .D/ An- Other
A * C D
?
<
@?
@<
:?
:<
=?
=<
;?
;<
A BG * G C ;G D@:G
-
8/20/2019 Cipla vs Ranbaxy Research Report
20/39
#es, 8hch Co%pan-s Pro(#ct Is H)h!- So!(
O#t
Ans, .A/ Cp!a .*/ Ran+a3-
CIPLA RAN*AY?
<
@?
@<
:?
:<
=?
=<
Chart !itle
A8is !itle
A8is !itle
(A) CIPLA 66%
(B) RANBAXY 34%
-
8/20/2019 Cipla vs Ranbaxy Research Report
21/39
#es, 'hi#h Com4any Gi9es You ;iher
ProEt
Ans, .A/ Cp!a .*/ Ran+a3-
;G
=G
ProEt Marin
CIPLA
RAN*ACY
(A) CIPLA 64%
(B) RANBA! "6%
-
8/20/2019 Cipla vs Ranbaxy Research Report
22/39
#es, Commonly You Sale Any Me5i#ine
&n !he Pres#ri4tion &@
Ans, .A/ Doctor
.*/ Che%st
.C/ M6R
.D/An- Other
DOCTORCHEMIST
M6RANY OTHER
?G
-
8/20/2019 Cipla vs Ranbaxy Research Report
23/39
-
8/20/2019 Cipla vs Ranbaxy Research Report
24/39
#es, Amon Ci4la Rana8y 'hi#h
Com4any You )oun5 Reliale
Ans, .A/ Cp!a .*/
Ran+a3-
:G
=G
Re!a+!t-
CIPLA
RAN*AY
.A/ CIPLA :G
.*/ RAN*AY =G
-
8/20/2019 Cipla vs Ranbaxy Research Report
25/39
#es, 12e Yo#r Sats"acton Le2e!
Ans, .A/ E3ce!!ent .*/ 1oo((C) Satisfactory (D) A!ra"!
ECELLENT 1OOD SATISFACTORY AVERA1E
?
:
;
@?
@:
@;
@
@
:?
(A) EXCELLENT 36%
(B) #OOD 34%
(C) SATIS$ACTORY &%
(D) A'ERA#E &%
-
8/20/2019 Cipla vs Ranbaxy Research Report
26/39
#es, 'hi#h Com4any Pro9i5es Most
:arious Promotional S#hemes !o You
Ans6 .A/ Cp!a
.*/Ran+a3-
CIPLA RAN*AY?G
-
8/20/2019 Cipla vs Ranbaxy Research Report
27/39
UE6@@ 8HICH TYPES OF SCHEMES ARE
OROVIDED *Y THE COMPANY TP YOU
ANS6 .A/ ETRA COMMISSION
.*/ 1OOD PROFIT MAR1IN
.C/ ANY SHORT OF CONTEST
?<
@?@<:?:<=?
:>
@=
(A) EXTRA COISSION 6%
(B) #OOD PRO$IT AR#IN *+%
(C) ANY S,ORT O$ CONTEST 6%
-
8/20/2019 Cipla vs Ranbaxy Research Report
28/39
UE6@: 8ETHER CONSUMER S8ITCH OVER
TO OTHER COMPANY
OR NOT IF THEIR *RAND IS NOT AVAILA*LE
ANS6 .A/ YES .NO/
YES NO?
<
@?
@<
:?
:<
=?
Chart !itle
A8is !itle
(A) YES 44%
(B) NO *6%
-
8/20/2019 Cipla vs Ranbaxy Research Report
29/39
UE6@= 8HICH PRODUCT YOU 8ILL SU11EST TO
THE CONSUMER
ANS6 .A/ CIPLA .*/
RAN*AY
G
=;G
Chart !itle
CIPLA
RAN*AY
(A) CIPLA 66%
(B) RANBAXY 34%
-
8/20/2019 Cipla vs Ranbaxy Research Report
30/39
UE6@; IN 8HICH SEASONAL VARIATION THE
DEMAND OF MEDICINE VARRIES
ANS6 .A SUMMER
.*/ 8INTER
.C/ ANY OTHER
SUMMER 8INTER ANY OTHER?
<
@?
@<
:?
:<
=?
=<
;?
Chart !itle
A8is !itle
(A) S-ER .%
(B) /INTER &%
(C) ANY OT,ER +%
-
8/20/2019 Cipla vs Ranbaxy Research Report
31/39
UE6@< 8HAT IS THE PRICE DIFFERENTIATION
*ET8EEN THE MEDICINE
ANS6 .A/ LESS .*/
CONSTANT
.C/ MORE .D/ VARIED
LESS
CONSTANT
MORE
VARIED
? < @? @< :? :< =?
@@
:;
B
Chart !itle
.A/ LESS ::G
.*/ CONSTANT ;G
.C/ MORE @;G
.D/ VARIED @G
-
8/20/2019 Cipla vs Ranbaxy Research Report
32/39
-
8/20/2019 Cipla vs Ranbaxy Research Report
33/39
FINDIN1S
• /! 0a! co12ar! ot0 2ro5cts o 1ay as!s 7i8! ra a75!9
2ro5ct 2ositioi"9 c5sto1!r 2r!f!r!c!9 :5a7ity9 2ric!9 !tc a
fo5 t0at Ci27a i a77 r!s2!cts !tt!r t0a Raa;y<
• D5ri" t0! s5r!y =! fo5 t0at 5>affara"ar 0as a 05"! 1ar8!t
of t0! 20ar1ac!5tica7 i5stry<
• ost of t0! 2!o27! 25rc0as!s 1!ici!s o7y =it0 cos57ti" Doctor
(!! for co11o is!as! ? sic8!ss) a 5s! 1!ici!s ras
2r!scri! y Doctors or 1!ica7 stor!s or R<• '!ry f!= 2!o27! 8o= ao5t 1!ici!s ras i
coscio5s
-
8/20/2019 Cipla vs Ranbaxy Research Report
34/39
LIMITATIONS
In e2er- st#(-pro5ect #n(erta0en !%tatons arses an( are
ne2ta+!e6
S%!ar!- n ths pro5ect se2era! !%tatons appear7 'hch 'o#!(
ha2e +een e!%nate( +- the #se o" t%e7 access+!t- to
n"or%aton has not +een poss+!e6
• T#i$ ro&ect i$ 'a$ed on 051a 2roc!ssi" ? aa7ysis T#erefore t#ere
are c#ance$ of #*man error
• +ne of t#e ma&or limitation$ i$ ti1! o5!!ss
• Trainee$ are not 'eing 2art of or"ai>atio T#e, are merel, con$idered
a$ trainee$
• Trainee$ are ro-ided wit# limited re$o*rce$ No finanal aid or $tiend i$
'eing aid to t#em $o t#e, can not $end m*c# on meeting$ wit# t#e
otential c*$tomer$ It can 'e al$o treated a$ a limitation of cost
o5!!ss
• La$t '*t not t#e lea$t i$ t#e limitation of ar!a o5!!ss
-
8/20/2019 Cipla vs Ranbaxy Research Report
35/39
SU11ESTIONS & RECOMMENDATIONS
• T0! co12ai!s s0o57 icr!as! a=ar!!ss of t0!ir 2ro5cts a
ras y 2ro2!r a!rtis!1!ts<
• A=ar!!ss of co11o 1!ici!s s0o57 ! icr!as!9 so t0at t0!y
ca ! 25rc0as! =it0o5t cos57tatio of octors i cas! of
!1!r"!cy<
• Pric!s of 1!ici!s s0o57 ! r!5c! as =! o= 0a! "!!ric ty2! of
1!ici!s =0ic0 2roi!s a 0i"0 2rofit 1ar"i to 1!iators9
r!s57ti" i icr!as! of 1ar8!t 2ric! of 1!ici!s t0at ca@t !
affora7! y co11o 2!o27!<
• E;2iry at! of 1!ici!s s0o57 ! Bo7 a c7!ar7y isi7!<
• Istr5ctios for 5s! s0o57 ! ic75! o 1!ici!s<
• O7i! s0o22i" of 1!ici!s (i
itro5c!<
• Raa;y s0o57 foc5s o its 1ar8!ti" ? 2ositioi" strat!"y to
o!rco1! t0! "a2 ? sa7!s i co12ariso to Ci27a
-
8/20/2019 Cipla vs Ranbaxy Research Report
36/39
Conc!#sons
-
8/20/2019 Cipla vs Ranbaxy Research Report
37/39
*+!o)raph-
-
8/20/2019 Cipla vs Ranbaxy Research Report
38/39
Anne3#re
-
8/20/2019 Cipla vs Ranbaxy Research Report
39/39